<DOC>
	<DOCNO>NCT02492737</DOCNO>
	<brief_summary>The purpose Phase I , multicenter study evaluate safety , pharmacokinetics , pharmacodynamics clinical activity AG-881 advance hematologic malignancy harbor IDH1 and/or IDH2 mutation</brief_summary>
	<brief_title>Study Orally Administered AG-881 Patients With Advanced Hematologic Malignancies With IDH1 and/or IDH2 Mutation</brief_title>
	<detailed_description>The first portion study dose escalation phase cohorts patient receive ascend oral dos AG-881 determine maximum tolerate dose ( MTD ) and/or recommend Phase II dose . The second portion study dose expansion phase patient receive AG-881 evaluate safety , tolerability , clinical activity recommend Phase II dose . Anticipated time study treatment disease progression unacceptable toxicity occur patient remove discretion investigator .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients must ≥18 year age Patients must document IDH1 and/or IDH2 genemutated disease Patients must advance hematologic malignancy IDH1 and/or IDH2 mutation Patient must able understand willing sign inform consent Patients must ECOG PS 0 2 Patients must adequate hepatic function evidence serum total bilirubin ≤1.5 upper limit normal ( ULN ) , unless consider due Gilbert 's disease leukemic involvement Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) ≤3.0 × ULN , unless consider due involvement neoplasm consideration treatment Patients must adequate renal function evidence serum creatinine ≤2.0 × ULN Creatinine clearance 40 mL/min base CockroftGault glomerular filtration rate ( GFR ) estimation Patients must recover clinically relevant toxic effect prior surgery , radiotherapy , therapy intend treatment cancer Female patient reproductive potential must negative serum pregnancy test within 7 day prior start therapy . Patients reproductive potential define sexually mature woman undergone hysterectomy , bilateral oophorectomy tubal occlusion naturally postmenopausal ( i.e. , menstruate ) least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) Patients undergone HSCT within 60 day Patients receive systemic anticancer therapy radiotherapy &lt; 14 day prior first day study drug administration Patients receive investigational agent &lt; 14 day prior Patients pregnant breast feed Patients active severe infection require antiinfective therapy unexplained fever &gt; 38.5°C Screening visit first day study drug administration ( discretion Investigator , patient tumor fever may enrol ) Patients New York Heart Association ( NYHA ) Class III IV congestive heart failure LVEF &lt; 40 % echocardiogram ( ECHO ) multigated acquisition ( MUGA ) scan within approximately 28 day C1D1 Patients history myocardial infarction within last 6 month Patients know unstable uncontrolled angina pectoris Patients known history severe and/or uncontrolled ventricular arrhythmia Patients QTc interval ≥450 msec factor increase risk QT prolongation arrhythmic event Patients take medication know prolong QT interval Patients know infection human immunodeficiency virus ( HIV ) active hepatitis B C Patients clinical symptom suggest active central nervous system ( CNS ) leukemia know CNS leukemia . Evaluation cerebrospinal fluid require clinical suspicion CNS involvement leukemia Screening Patients immediately lifethreatening , severe complication hematologic malignancy uncontrolled bleeding , pneumonia hypoxia shock , and/or disseminate intravascular coagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>dual mutation</keyword>
	<keyword>MPN</keyword>
	<keyword>AITL</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>IDH1</keyword>
	<keyword>IDH2</keyword>
	<keyword>AG-881</keyword>
</DOC>